Ads
related to: current research on hemophilia treatment- Cost And Coverage
Information On Financial Programs &
Aid For Patients With Hemophilia A.
- Pharmacology Information
Find More Information About
a Treatment Option.
- Prophylaxis Information
Keep Your Patients With
Hemophilia A Protected From Bleeds.
- Dosing & Administration
Information on Dosing,
Reconstitution and Administration.
- Dosing And Administration
Information For HCPs On Dosing,
Reconstitution and Administration.
- Physician Resources
Professional Educational Resources
On A Hemophilia A Treatment Option.
- Cost And Coverage
Search results
Results From The WOW.Com Content Network
Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves rather than the current standard of care, which requires regular intravenous infusions of FIX that ...
In the US, fidanacogene elaparvovec is indicated for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy; or have current or historical life-threatening hemorrhage; or have repeated, serious spontaneous bleeding episodes; and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var ...
The National Bleeding Disorders Foundation (NBDF) is a United States patient advocacy organization for the care and treatment of inheritable blood and bleeding disorders such as hemophilia and von Willebrand disease. Founded in 1948, NBDF, then known as the National Hemophilia Foundation, helps secure funding for treatment centers and develops ...
NEWARK, Del, June 25, 2024 (GLOBE NEWSWIRE) -- The hemophilia treatment market is forecast to reach USD 12.1 billion in 2024. Between 2024 and 2034, hemophilia treatment is predicted to register a CAGR of 4.4%. Worldwide, the hemophilia treatment market is expected to reach USD 18.7 billion by 2034.
Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia A and hemophilia B. [5] [8] It is an anti-tissue factor pathway inhibitor. [5] [8] The most common adverse reactions include injection site reactions and hives (urticaria). [11]
Recombinant factor VIIa (rfVIIa) is a form of blood factor VII that has been manufactured via recombinant technology. [4] [5] It is administered via an injection into a vein.[6] [4] [5] It is used to treat bleeding episodes in people who have acquired haemophilia, among other indications. [7]
Ads
related to: current research on hemophilia treatment